SG Americas Securities LLC Purchases 545,767 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX)

SG Americas Securities LLC grew its stake in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 138.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 940,784 shares of the company's stock after acquiring an additional 545,767 shares during the period. SG Americas Securities LLC owned 0.68% of Compass Therapeutics worth $1,787,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in CMPX. Rhumbline Advisers boosted its stake in Compass Therapeutics by 3.1% in the 4th quarter. Rhumbline Advisers now owns 129,116 shares of the company's stock valued at $187,000 after purchasing an additional 3,822 shares during the period. Invesco Ltd. increased its position in Compass Therapeutics by 11.3% during the 4th quarter. Invesco Ltd. now owns 39,483 shares of the company's stock worth $57,000 after buying an additional 4,018 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Compass Therapeutics by 2.6% during the fourth quarter. Bank of New York Mellon Corp now owns 237,975 shares of the company's stock worth $345,000 after buying an additional 6,041 shares in the last quarter. ProShare Advisors LLC lifted its holdings in shares of Compass Therapeutics by 49.0% during the fourth quarter. ProShare Advisors LLC now owns 28,722 shares of the company's stock worth $42,000 after buying an additional 9,451 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in shares of Compass Therapeutics by 31.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 46,942 shares of the company's stock valued at $69,000 after acquiring an additional 11,326 shares during the period. Institutional investors own 68.43% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on CMPX shares. Piper Sandler initiated coverage on shares of Compass Therapeutics in a research report on Wednesday, February 19th. They set an "overweight" rating and a $12.00 price target on the stock. Wedbush reaffirmed an "outperform" rating and set a $8.00 target price on shares of Compass Therapeutics in a report on Tuesday, April 1st. Guggenheim dropped their price target on shares of Compass Therapeutics from $12.00 to $10.00 and set a "buy" rating for the company in a research report on Friday, May 9th. HC Wainwright reiterated a "buy" rating and issued a $24.00 price target on shares of Compass Therapeutics in a research note on Monday, April 21st. Finally, Leerink Partnrs upgraded Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 1st. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $13.13.

Compass Therapeutics Stock Performance

Shares of Compass Therapeutics stock traded up $0.19 on Thursday, reaching $2.38. 765,396 shares of the stock were exchanged, compared to its average volume of 952,958. The firm has a market cap of $329.11 million, a PE ratio of -5.80 and a beta of 1.41. The firm's 50 day moving average is $2.04 and its 200-day moving average is $2.20. Compass Therapeutics, Inc. has a one year low of $0.77 and a one year high of $4.08.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.12) EPS for the quarter, meeting the consensus estimate of ($0.12). On average, equities research analysts expect that Compass Therapeutics, Inc. will post -0.36 EPS for the current fiscal year.

Insider Transactions at Compass Therapeutics

In related news, insider Jonathan Anderman bought 20,000 shares of the company's stock in a transaction dated Monday, April 7th. The stock was purchased at an average price of $1.54 per share, with a total value of $30,800.00. Following the completion of the acquisition, the insider now owns 21,000 shares of the company's stock, valued at $32,340. The trade was a 2,000.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Carl L. Gordon sold 3,571,428 shares of the firm's stock in a transaction that occurred on Wednesday, April 9th. The shares were sold at an average price of $1.59, for a total transaction of $5,678,570.52. The disclosure for this sale can be found here. 29.80% of the stock is owned by insiders.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.